NHS RSV Antibody Jab for Premature Babies Rollout
NHS to Shield Thousands of Premature Babies with Groundbreaking RSV Jab
Table of Contents
London,UK – July 24,2025 – The National Health Service (NHS) in England is set to launch a vital new immunisation program this September,offering a long-lasting “suit of armour” against Respiratory Syncytial Virus (RSV) to thousands of premature babies. This proactive measure aims to considerably reduce hospitalisations and severe illness during the critical winter months,providing vulnerable infants with crucial protection from birth.
A Protective Bubble for the Most Vulnerable
Dr. Claire Fuller,Co-National Medical Director for NHS England,highlighted the significance of this new jab. “This injection will provide premature babies with a protective bubble against RSV just in time for the colder months,” she stated. “It will offer a long-lasting defence, helping to avoid unnecessary hospitalisations and serious illness, giving babies the best possible start in life and shielding them from harm.”
The new medication, nirsevimab, represents a meaningful advancement in protecting infants from RSV, a common respiratory virus that can cause serious illness in young children, particularly those born prematurely.
Understanding Nirsevimab’s Mechanism
Nirsevimab operates differently from the RSV vaccine offered to pregnant women. While the maternal vaccine boosts the mother’s immune system to create protective antibodies passed to the baby in the womb, providing protection from birth, babies born before 32 weeks gestation have limited or no protection from these vaccinations. Nirsevimab directly provides these essential antibodies to the infant, offering immediate and sustained protection.
Addressing a Critical Health Risk
John Stewart, Director of Specialised Commissioning at NHS England, emphasised the severity of RSV for premature infants. “For babies born very prematurely, the risk of contracting RSV in their first winter is high and extremely serious,” he explained. “This new medication will provide vulnerable infants with their suit of armour that protects against what can be a life-threatening infection.”
Stewart expressed his delight at the upcoming rollout.”I am delighted that we will be able to offer nirsevimab to protect these babies from this winter onwards, and I’m extremely grateful to colleagues in specialist neonatal clinics across the country who will deliver this life-saving service.”
Government Commitment to Prevention
Minister for Public Health and Prevention Ashley Dalton lauded the initiative as a key step in the government’s public health strategy.”This is excellent news for thousands of vulnerable babies and their families,” Dalton said. “By rolling out nirsevimab this September, we’re ensuring that our most at-risk infants, including those who are born too early to benefit from maternal vaccination, are protected in the best possible way.”
He added,”This rollout is a prime example of how this government is shifting the focus from sickness to prevention,as part of our 10 Year health Plan.”
Expert Endorsement and Future Outlook
Dr. Conall Watson, consultant epidemiologist at the UK Health Security Agency (UKHSA), underscored the importance of both maternal vaccination and nirsevimab. “Having an RSV vaccine from week 28 in every pregnancy is key to protecting your baby against RSV bronchiolitis. Most RSV hospital admissions in babies can be prevented by vaccination,” he noted.
Dr. Watson further elaborated on the role of nirsevimab: “This new NHS nirsevimab immunisation programme will offer critical protection for very premature babies born before mum’s antenatal vaccination can protect them. UKHSA has been working closely with JCVI and the NHS to provide evidence in support of this programme, and we are delighted to see this launch ahead of winter 2025.”
The introduction of nirsevimab marks a significant milestone in safeguarding the health of the UK’s youngest and most vulnerable population, reinforcing the NHS’s commitment to preventative healthcare and ensuring the best possible start for every baby.